CA2668693A1 - Therapeutic uses of tim-3 modulators - Google Patents

Therapeutic uses of tim-3 modulators Download PDF

Info

Publication number
CA2668693A1
CA2668693A1 CA002668693A CA2668693A CA2668693A1 CA 2668693 A1 CA2668693 A1 CA 2668693A1 CA 002668693 A CA002668693 A CA 002668693A CA 2668693 A CA2668693 A CA 2668693A CA 2668693 A1 CA2668693 A1 CA 2668693A1
Authority
CA
Canada
Prior art keywords
tim
agent
polypeptide
galectin
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002668693A
Other languages
English (en)
French (fr)
Inventor
David E. Anderson
Ana C. Anderson
Vijay K. Kuchroo
David A. Hafler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2668693A1 publication Critical patent/CA2668693A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
CA002668693A 2006-11-15 2007-11-15 Therapeutic uses of tim-3 modulators Abandoned CA2668693A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85939106P 2006-11-15 2006-11-15
US60/859,391 2006-11-15
US92394507P 2007-04-17 2007-04-17
US60/923,945 2007-04-17
PCT/US2007/024067 WO2008060617A2 (en) 2006-11-15 2007-11-15 Therapeutic uses of tim-3 modulators

Publications (1)

Publication Number Publication Date
CA2668693A1 true CA2668693A1 (en) 2008-05-22

Family

ID=39402274

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002668693A Abandoned CA2668693A1 (en) 2006-11-15 2007-11-15 Therapeutic uses of tim-3 modulators

Country Status (6)

Country Link
US (1) US20100061992A1 (enExample)
EP (1) EP2081961A2 (enExample)
JP (1) JP2010510223A (enExample)
AU (1) AU2007319806A1 (enExample)
CA (1) CA2668693A1 (enExample)
WO (1) WO2008060617A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084999A1 (en) * 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
MX2011010050A (es) * 2009-03-25 2011-12-14 Univ Texas Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
HUE040213T2 (hu) 2010-06-11 2019-02-28 Kyowa Hakko Kirin Co Ltd Anti-TIM antitest
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
CA2916638C (en) 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
CN104853776B (zh) 2012-10-12 2021-04-09 布里格姆及妇女医院股份有限公司 免疫应答的增强
DK2911676T3 (da) 2012-10-29 2020-08-03 Univ Arkansas Hidtil ukendte mukosale adjuvanser og afgivelsessystemer
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
ES3040431T3 (en) * 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
SMT202100116T1 (it) 2014-05-28 2021-05-07 Agenus Inc Anticorpi anti-gitr e metodi di utilizzo degli stessi
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
WO2016171722A1 (en) * 2015-04-24 2016-10-27 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
WO2016179194A1 (en) * 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
CA2986705A1 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
EP3383430A4 (en) 2015-12-02 2019-12-18 Agenus Inc. ANTIBODIES AND METHOD FOR USE THEREOF
MX394409B (es) * 2016-03-04 2025-03-24 Galectin Sciences Llc Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.
FR3051192B1 (fr) * 2016-05-13 2020-12-25 Univ De Lorraine Methode de purification de proteines recombinantes par affinite basee sur l'activite lectinique du domaine crd d'une galectine
MA45123A (fr) 2016-05-27 2019-04-10 Agenus Inc Anticorps anti-tim-3 et leurs méthodes d'utilisation
AU2017297506A1 (en) 2016-07-14 2019-02-21 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
CA3062648A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
AU2018308088B2 (en) * 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
JP2022523333A (ja) 2019-01-30 2022-04-22 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体およびその使用
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
KR102536302B1 (ko) * 2020-02-25 2023-05-26 국립암센터 Tim-3 에 특이적으로 결합하는 단일클론항체 및 이의 용도
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303082B2 (en) * 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
BRPI0414924A (pt) * 2003-10-03 2006-11-07 Brigham & Womens Hospital ligantes de tim-3 e seus métodos

Also Published As

Publication number Publication date
WO2008060617A2 (en) 2008-05-22
EP2081961A2 (en) 2009-07-29
AU2007319806A1 (en) 2008-05-22
US20100061992A1 (en) 2010-03-11
WO2008060617A3 (en) 2008-12-24
JP2010510223A (ja) 2010-04-02

Similar Documents

Publication Publication Date Title
US20100061992A1 (en) Therapeutic uses of tim-3 modulators
AU2022200016B2 (en) Cancer vaccines and methods of treatment using the same
US11529416B2 (en) Vista modulators for diagnosis and treatment of cancer
JP4903128B2 (ja) Ｔｉｍ−１、ｔｉｍ−２、およびｔｉｍ−４の機能を調節することによって免疫応答を調節する方法
AU2013277051B2 (en) Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20170216403A1 (en) Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
JP7026047B2 (ja) 免疫調節剤を併用するがんの治療
KR20210044221A (ko) Pd1-4-1bbl 변이체 융합 단백질 및 이의 사용 방법
ES2939112T3 (es) Composiciones y métodos de uso de interleucina-10 en combinación con inhibidores de vías de puntos de control inmunitario
KR20190102267A (ko) Psgl-1 길항제 및 그의 용도
CN110573522A (zh) SIRPα-41BBL融合蛋白及其使用方法
NZ583821A (en) Cdh3 peptide and medicinal agent comprising the same
CA3168469A1 (en) Cho cell expressing il-15 heterodimers
JP4989850B2 (ja) ＴＧＦ−βの遮断により腫瘍再発を防ぐ方法
CN101027392B (zh) 通过调节tim-1、tim-2和tim-4功能从而调节免疫应答的方法
US20100297146A1 (en) Immune system programming through b7-dc

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20131115